Want to see HK:0241 full AI Analyst Report?
Top Page
Alibaba Health Information Technology
(0241)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$3.00
▼(-6.25% Downside)
Action:Reiterated
Date:10/10/26
The score is driven primarily by solid financial fundamentals—especially a very conservative, low-debt balance sheet and improved profitability—offset by weaker cash flow quality and slowing recent revenue growth. Technicals are a notable drag due to a clear downtrend (price below key moving averages and negative MACD), while valuation is moderate with a supportive dividend yield.
Positive Factors
Conservative Balance Sheet
Extremely low leverage gives Alibaba Health substantial financial resilience and reduces interest and refinancing pressure. Growing equity alongside earnings provides a stronger capital base, preserving flexibility to invest in healthcare platforms, products, and services through changing conditions.
Negative Factors
Decelerating Revenue Growth
Recent top-line growth has slowed sharply after the company’s earlier expansion, which may limit operating leverage and reduce the pace at which earnings can compound. Continued deceleration would make it harder to absorb fixed platform costs and sustain improving profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage gives Alibaba Health substantial financial resilience and reduces interest and refinancing pressure. Growing equity alongside earnings provides a stronger capital base, preserving flexibility to invest in healthcare platforms, products, and services through changing conditions.
Read all positive factors
Alibaba Health Information Technology (0241) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$45.68B
Dividend Yield2.49%
Average Volume (3M)61.87M
Price to Earnings (P/E)20.1
Beta (1Y)1.94
Revenue Growth14.03%
EPS Growth36.55%
CountryHK
Employees1,394
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.12
Shares Outstanding16,175,301,000
10 Day Avg. Volume62,513,986
30 Day Avg. Volume61,866,672
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)3.73
Price to Sales (P/S)1.94
P/FCF Ratio54.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.21Price Target Upside31.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)HK$37.23B
Alibaba Health Information Technology Business Overview & Revenue Model
Company Description
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The compa...
How the Company Makes Money
Alibaba Health primarily makes money by monetizing healthcare product sales and platform-based services. Key revenue streams generally include: (1) Direct sales of pharmaceutical and healthcare products: the company sells medicines and other healt...
Alibaba Health Information Technology Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.26B | 30.60B | 27.03B | 26.76B | 20.58B |
| Gross Profit | 8.21B | 7.43B | 5.90B | 5.70B | 4.11B |
| EBITDA | 1.47B | 1.62B | 999.05M | 12.21M | -188.12M |
| Net Income | 1.94B | 1.43B | 883.48M | 535.65M | -265.56M |
Balance Sheet | |||||
| Total Assets | 23.02B | 21.18B | 19.71B | 20.75B | 19.20B |
| Cash, Cash Equivalents and Short-Term Investments | 10.45B | 8.10B | 9.55B | 10.92B | 10.55B |
| Total Debt | 59.56M | 35.52M | 82.17M | 77.80M | 135.41M |
| Total Liabilities | 5.22B | 4.87B | 5.19B | 5.60B | 5.13B |
| Stockholders Equity | 17.80B | 16.31B | 14.54B | 15.17B | 14.10B |
Cash Flow | |||||
| Free Cash Flow | 1.23B | 1.38B | 1.06B | 250.08M | 409.43M |
| Operating Cash Flow | 1.24B | 1.40B | 1.08B | 255.69M | 424.36M |
| Investing Cash Flow | 2.02B | -2.60B | -4.88B | -532.44M | 1.87B |
| Financing Cash Flow | -14.22M | -72.52M | -1.98B | -111.28M | -58.63M |
Alibaba Health Information Technology Technical Analysis
Negative
3.20
Price Trends
2.97
Negative
3.09
Negative
3.97
Negative
Market Momentum
-0.04
Positive
36.80
Neutral
3.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0241, the sentiment is Negative. The current price of 3.2 is above the 20-day moving average (MA) of 2.86, above the 50-day MA of 2.97, and below the 200-day MA of 3.97, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.80 is Neutral, neither overbought nor oversold. The STOCH value of 3.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0241.
Alibaba Health Information Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% | |
65 Neutral | HK$50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% | |
64 Neutral | HK$45.68B | 20.09 | 10.95% | 2.49% | 14.03% | 36.55% | |
61 Neutral | HK$64.52B | 11.88 | 6.21% | 5.88% | 9.12% | -3.22% | |
57 Neutral | HK$11.76B | 20.98 | 4.62% | 160.60% | 7.92% | 152.75% | |
52 Neutral | HK$3.05B | 36.94 | 1.88% | 1.40% | 16.87% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0241
Alibaba Health Information Technology
2.83
-2.62
-48.07%
HK:1833
Ping An Healthcare and Technology Company
5.44
-8.30
-60.41%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.11
0.04
0.41%
HK:1099
Sinopharm Group Co
16.19
-2.24
-12.16%
HK:2158
Yidu Tech, Inc.
2.86
-2.77
-49.21%
HK:2192
Medlive Technology Co., Ltd.
6.31
-3.81
-37.66%
Alibaba Health Information Technology Corporate Events
Alibaba Health Grants 7.67 Million RSUs Under 2024 Share Award Scheme
Sep 15, 2026
Alibaba Health Information Technology Limited has granted 7,672,500 restricted share units to 16 employees under its 2024 Share Award Scheme, with no purchase price attached and each unit representing a right to receive a share upon vesting. The a...
Alibaba Health installs new chairman and CEO from Alibaba Group in leadership overhaul
Sep 11, 2026
Alibaba Health Information Technology Limited has announced a major leadership reshuffle effective after business closes on September 11, 2026, appointing long-time Alibaba Group executive Yu Yong as executive director, chairman, chief executive o...
Alibaba Health Reshapes Board and Committees to Strengthen Governance
Sep 11, 2026
Alibaba Health Information Technology Limited has updated its board composition effective from the close of business on September 11, 2026, appointing Yu Yong as chairman and chief executive officer alongside executive directors Shen Difan and She...
Alibaba Health Shareholders Approve AGM Resolutions and Large Cash Dividends
Aug 7, 2026
Alibaba Health Information Technology Limited reported that all resolutions at its 7 August 2026 annual general meeting in Hangzhou were duly passed by shareholders via poll. The meeting approved the audited financial statements for the year ended...
Alibaba Health Declares Final Dividend and Updates HKD Payout Terms
Aug 7, 2026
Alibaba Health Information Technology Limited has declared a final ordinary cash dividend of RMB 0.0595 per share for the financial year ended 31 March 2026, with shareholder approval obtained on 7 August 2026. The dividend will be paid in Hong Ko...
Alibaba Health Declares Special Cash Dividend for FY2026
Aug 7, 2026
Alibaba Health Information Technology Limited has declared a special cash dividend for shareholders for the financial year ended March 31, 2026, reinforcing its position as a healthcare technology company that returns capital to investors. The sha...
Alibaba Health Announces Resignation of Non-Executive Director Xu Haipeng
Jul 29, 2026
Alibaba Health Information Technology Limited has announced the resignation of non-executive director Mr. Xu Haipeng, effective July 29, 2026, as he plans to devote more time to his personal commitments and development. The board emphasized that M...
Alibaba Health Reshapes Board and Committees to Bolster Governance
Jul 29, 2026
Alibaba Health Information Technology Limited has updated its board composition, effective July 29, 2026, appointing Shen Difan as chairman and chief executive officer alongside executive director Sheng Mengyue and non-executive director Huang Jia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.